{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:04:17Z","timestamp":1760299457465,"version":"3.41.0"},"reference-count":54,"publisher":"Impact Journals, LLC","issue":"49","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,12,6]]},"DOI":"10.18632\/oncotarget.13146","type":"journal-article","created":{"date-parts":[[2016,11,7]],"date-time":"2016-11-07T14:56:13Z","timestamp":1478530573000},"page":"81555-81570","source":"Crossref","is-referenced-by-count":14,"title":["Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of \u03b2-catenin and mTORC1\/2"],"prefix":"10.18632","volume":"7","author":[{"given":"Beatrice","family":"Riva","sequence":"first","affiliation":[{"name":"Department of Pharmacological Sciences, Universit\u00e0 del Piemonte Orientale \u201cA. Avogadro\u201d, 28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco De","family":"Dominici","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia 19107, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Gnemmi","sequence":"additional","affiliation":[{"name":"Department of Pharmacological Sciences, Universit\u00e0 del Piemonte Orientale \u201cA. Avogadro\u201d, 28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samanta A.","family":"Mariani","sequence":"additional","affiliation":[{"name":"MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh EH16 4TJ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Minassi","sequence":"additional","affiliation":[{"name":"Department of Pharmacological Sciences, Universit\u00e0 del Piemonte Orientale \u201cA. Avogadro\u201d, 28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Minieri","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia 19107, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Salomoni","sequence":"additional","affiliation":[{"name":"Samantha Dickson Brain Cancer Unit, University College London Cancer Institute, London WC1E 6BT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Canonico","sequence":"additional","affiliation":[{"name":"Department of Pharmacological Sciences, Universit\u00e0 del Piemonte Orientale \u201cA. Avogadro\u201d, 28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando A.","family":"Genazzani","sequence":"additional","affiliation":[{"name":"Department of Pharmacological Sciences, Universit\u00e0 del Piemonte Orientale \u201cA. Avogadro\u201d, 28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Calabretta","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia 19107, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Condorelli","sequence":"additional","affiliation":[{"name":"Department of Pharmacological Sciences, Universit\u00e0 del Piemonte Orientale \u201cA. Avogadro\u201d, 28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,11,7]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.canlet.2006.11.032","article-title":"Celecoxib induces apoptosis in COX2 deficient human gastric cancer cells through Akt\/GSK3beta\/NAG-1 pathway","volume":"251","author":"Hu","year":"2007","journal-title":"Cancer Lett"},{"key":"2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/gut.50.6.857","article-title":"A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis","volume":"50","author":"Steinbach","year":"2002","journal-title":"Gut"},{"key":"3","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","article-title":"The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis","volume":"342","author":"Godio","year":"2000","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0090-4295(98)00513-5","article-title":"Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis","volume":"53","author":"Olsson","year":"1999","journal-title":"Urology"},{"key":"5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0006-2952(96)00181-5","article-title":"Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway","volume":"52","author":"Rigas","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1158\/0008-5472.CAN-07-5555","article-title":"Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib","volume":"68","author":"Schonthal","year":"2008","journal-title":"Cancer Res"},{"key":"7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4161\/cbt.4.5.1699","article-title":"Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo","volume":"4","author":"Schonthal","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"8","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/sj.bjc.6604049","article-title":"Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy","volume":"97","author":"Schonthal","year":"2007","journal-title":"Br J Cancer"},{"key":"9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.canlet.2011.01.012","article-title":"Targeting apoptosis pathways by Celecoxib in cancer","volume":"332","author":"Jendrossek","year":"2013","journal-title":"Cancer Lett"},{"key":"10","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1158\/1535-7163.MCT-06-0629","article-title":"Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib","volume":"6","author":"Schonthal","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"11","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.3171\/foc.2006.20.4.14","article-title":"Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy","volume":"20","author":"Schonthal","year":"2006","journal-title":"Neurosurg Focus"},{"key":"12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/jnci\/94.8.585","article-title":"Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells","volume":"94","author":"Chen","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR? agonists","volume":"525","author":"Chr\u00e9tien","year":"2015","journal-title":"Nature"},{"key":"14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canlet.2012.08.006","article-title":"Selective elimination of leukemia stem cells: hitting a moving target","volume":"338","author":"Jamieson","year":"2013","journal-title":"Cancer Lett"},{"key":"15","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Sawyers","year":"2001","journal-title":"Science"},{"key":"16","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2013-01-481184","article-title":"Ubiquitin-mediated interaction of p210 BCR-ABL with beta-catenin supports disease progression in a murine model for chronic myelogenous leukemia","volume":"122","author":"Whitehead","year":"2013","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/ijc.26102","article-title":"beta-catenin as a potential key target for tumor suppression","volume":"129","author":"Zhu","year":"2011","journal-title":"Int J Cancer"},{"key":"18","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/sj.emboj.7601485","article-title":"Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation","volume":"26","author":"Gambacorti-Passerini","year":"2007","journal-title":"EMBO J"},{"key":"19","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","article-title":"Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML","volume":"10","author":"Armstrong","year":"2012","journal-title":"Cell Stem Cell"},{"key":"20","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.devcel.2007.04.001","article-title":"Functional redundancy of GSK-3alpha and GSK-3beta in Wnt\/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines","volume":"12","author":"Woodgett","year":"2007","journal-title":"Dev Cell"},{"key":"21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.stem.2012.03.006","article-title":"Targeting beta-catenin in CML: leukemia stem cells beware!","volume":"10","author":"Levine","year":"2012","journal-title":"Cell Stem Cell"},{"key":"22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Reya","year":"2007","journal-title":"Cancer Cell"},{"key":"23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/beta-catenin signaling: components, mechanisms, and diseases","volume":"17","author":"He","year":"2009","journal-title":"Dev Cell"},{"key":"24","first-page":"e192","article-title":"p16INK4a is a beta-catenin target gene and indicates low survival in human colorectal tumors","volume":"136","author":"Jung","year":"2009","journal-title":"Gastroenterology"},{"key":"25","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1128\/MCB.19.8.5696","article-title":"Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf\/Lef transcription but not activation of c-myc expression","volume":"19","author":"Fearon","year":"1999","journal-title":"Mol Cell Biol"},{"key":"26","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.bbagen.2012.08.010","article-title":"On the role of Wnt\/beta-catenin signaling in stem cells","volume":"1830","author":"Kuhl","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"27","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.cell.2006.06.055","article-title":"TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth","volume":"126","author":"MacDougald","year":"2006","journal-title":"Cell"},{"key":"28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12154-008-0003-5","article-title":"Rapamycin and mTOR kinase inhibitors","volume":"1","author":"Lin","year":"2008","journal-title":"J Chem Biol"},{"key":"29","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Sabatini","year":"2012","journal-title":"Cell"},{"key":"30","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.cell.2006.08.025","article-title":"Mind the GAP: Wnt steps onto the mTORC1 train","volume":"126","author":"Blenis","year":"2006","journal-title":"Cell"},{"key":"31","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/jcb.23053","article-title":"Regulation of AMP-activated protein kinase by LKB1 and CaMKK in adipocytes","volume":"112","author":"Goransson","year":"2011","journal-title":"J Cell Biochem"},{"key":"32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Guan","year":"2003","journal-title":"Cell"},{"key":"33","unstructured":"Study of AR-12 in adult patients with advanced or recurrent solid tumors or lymphoma. 2013."},{"key":"34","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1182\/blood-2004-05-1957","article-title":"A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"35","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Moller","year":"2001","journal-title":"J Clin Invest"},{"key":"36","first-page":"285","article-title":"The problem of synergism and antagonism of combined drugs","volume":"3","author":"Loewe","year":"1953","journal-title":"Arzneimittelforschung"},{"key":"37","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Skorski","year":"2010","journal-title":"J Clin Invest"},{"key":"38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2004.11.002","article-title":"Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro","volume":"224","author":"Reddanna","year":"2005","journal-title":"Cancer Lett"},{"key":"39","first-page":"6045","article-title":"Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models","volume":"60","author":"DuBois","year":"2000","journal-title":"Cancer Res"},{"key":"40","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ajh.20542","article-title":"Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of COX2 expression and are synergistic with hydroxyurea or imatinib","volume":"81","author":"Li","year":"2006","journal-title":"Am J Hematol"},{"key":"41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.molcel.2005.03.027","article-title":"AMP-activated protein kinase induces a p53-dependent metabolic checkpoint","volume":"18","author":"Thompson","year":"2005","journal-title":"Mol Cell"},{"key":"42","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrc3960","article-title":"Forging a signature of in vivo senescence","volume":"15","author":"Sherr","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"43","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1","volume":"13","author":"Guan","year":"2011","journal-title":"Nat Cell Biol"},{"key":"44","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood-2011-06-361261","article-title":"Targeting of GSK3beta promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells","volume":"119","author":"Coluccia","year":"2012","journal-title":"Blood"},{"key":"45","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1096\/fj.04-3274fje","article-title":"Targeting the beta-catenin\/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells","volume":"19","author":"Grosch","year":"2005","journal-title":"FASEB J"},{"key":"46","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Hunter","year":"2009","journal-title":"J Clin Invest"},{"key":"47","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/nrc2254","article-title":"Role of autophagy in cancer","volume":"7","author":"White","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"48","doi-asserted-by":"crossref","first-page":"12469","DOI":"10.1073\/pnas.1005114107","article-title":"Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells","volume":"107","author":"Platanias","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"49","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0090-9556(24)15094-5","article-title":"Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats","volume":"28","author":"Burton","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"50","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1182\/blood-2006-02-005579","article-title":"Activation of a novel Bcr\/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells","volume":"109","author":"Donato","year":"2007","journal-title":"Blood"},{"key":"51","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Melo","year":"2000","journal-title":"Blood"},{"key":"52","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and Lyn kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Talpaz","year":"2003","journal-title":"Blood"},{"key":"53","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/op800158w","article-title":"An improved and scalable process for celecoxib: a selective cyclooxygenase-2 inhibitor","volume":"13","author":"Reddy","year":"2009","journal-title":"Org Process Res Dev"},{"key":"54","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.bjp.0707608","article-title":"Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells","volume":"153","author":"Canonico","year":"2008","journal-title":"Br J Pharmacol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T02:25:03Z","timestamp":1749695103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,7]]},"references-count":54,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2016,12,6]]}},"alternative-id":["13146","27835591"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13146","relation":{},"ISSN":["1949-2553"],"issn-type":[{"type":"electronic","value":"1949-2553"}],"subject":[],"published":{"date-parts":[[2016,11,7]]}}}